- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00053014
S0125, Chemotherapy, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Older Patients With Acute Myeloid Leukemia
S0125, A Phase II Study Of Chimerism-Mediated Immunotherapy (CMI) Using Nonmyeloablative Allogeneic Peripheral Blood Stem Cell Transplantation In Older Patients With Acute Myeloid Leukemia (AML) In First Complete Remission (A BMT Study)
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy and radiation therapy. Sometimes the transplanted cells can make an immune response against the body's normal tissues. Cyclosporine and mycophenolate mofetil may prevent this from happening.
PURPOSE: Phase II trial to study the effectiveness of chemotherapy and total-body irradiation followed by donor peripheral stem cell transplantation, cyclosporine, and mycophenolate mofetil in treating older patients who have acute myeloid leukemia.
연구 개요
상태
정황
상세 설명
Primary objective:
- Determine whether allogeneic peripheral blood stem cell transplantation with pre-conditioning low dose total body irradiation and fludarabine followed by cyclosporine and mycophenolate mofetil, when given to elderly patients with acute myeloid leukemia in first complete remission, is sufficiently efficacious (in terms of survival 1 year after transplantation) to warrant a phase III investigation.
Secondary objective:
- Determine the frequency and severity of toxic effects of this regimen in these patients.
Other objectives as funding permits:
- Determine whether chimerism patterns in bone marrow and blood after transplantation are associated with relapse and/or graft-versus-host disease (GVHD) in these patients.
- Determine whether cytogenic, immunophenotypic, and molecular biologic features detected in pre- and post-transplantation specimens are related to transplant outcomes and risk of relapse in these patients.
OUTLINE: This is an open-label study.
- Conditioning regimen: Patients receive fludarabine IV over 1 hour on days -4 to -2. Patients also undergo total body irradiation on day 0.
- Peripheral blood stem cell infusion (PBSC): Patients receive unmodified filgrastim transplantation (G-CSF)-mobilized donor PBSC on day 0.
- Post-transplantation immunosuppression: Patients receive oral cyclosporine on days -3 to 35 followed by a taper until day 180. Patients also receive oral mycophenolate mofetil on day 0 to 27 without tapering.
- Donor lymphocyte infusions (DLI): Patients with relapsed disease receive DLI IV over 30 minutes for up to 2 infusions.
Patients are followed every 3 months for 1 year, every 6 months for 1 year, and then annually for 3 years.
PROJECTED ACCRUAL: A total of 25-51 patients will be accrued for this study.
연구 유형
등록 (실제)
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
Arizona
-
Phoenix, Arizona, 미국, 85006
- Banner Good Samaritan Medical Center
-
Tucson, Arizona, 미국, 85723
- Veterans Affairs Medical Center - Tucson
-
Tucson, Arizona, 미국, 85724
- Arizona Cancer Center at University of Arizona Health Sciences Center
-
-
Arkansas
-
Little Rock, Arkansas, 미국, 72205
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
-
Little Rock, Arkansas, 미국, 72205
- Veterans Affairs Medical Center - Little Rock
-
-
California
-
Duarte, California, 미국, 91010-3000
- City of Hope Comprehensive Cancer Center
-
La Jolla, California, 미국, 92037-1027
- Scripps Cancer Center at Scripps Clinic
-
Los Angeles, California, 미국, 90033
- USC/Norris Comprehensive Cancer Center and Hospital
-
Los Angeles, California, 미국, 90095-1678
- Jonsson Comprehensive Cancer Center at UCLA
-
Martinez, California, 미국, 94553
- Veterans Affairs Outpatient Clinic - Martinez
-
Orange, California, 미국, 92868
- Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center
-
Sacramento, California, 미국, 95816
- Sutter Cancer center
-
Sacramento, California, 미국, 95817
- University of California Davis Cancer Center
-
Stanford, California, 미국, 94305-5408
- Stanford Cancer Center at Stanford University Medical Center
-
Travis Air Force Base, California, 미국, 94535
- General Robert Huyser Cancer Center at David Grant Medical Center
-
Walnut Creek, California, 미국, 94598
- John Muir/Mt. Diablo Comprehensive Cancer Center
-
-
Colorado
-
Aurora, Colorado, 미국, 80010
- University of Colorado Cancer Center at University of Colorado Health Sciences Center
-
Denver, Colorado, 미국, 80220
- Veterans Affairs Medical Center - Denver
-
-
Florida
-
Tampa, Florida, 미국, 33612
- Veterans Affairs Medical Center - Tampa (Haley)
-
-
Georgia
-
Atlanta, Georgia, 미국, 30342-1701
- CCOP - Atlanta Regional
-
Decatur, Georgia, 미국, 30033
- Charles B. Eberhart Cancer Center at DeKalb Medical Center
-
Fort Gordon, Georgia, 미국, 30905-5650
- Dwight David Eisenhower Army Medical Center
-
-
Hawaii
-
Honolulu, Hawaii, 미국, 96813
- Cancer Research Center of Hawaii
-
Honolulu, Hawaii, 미국, 96813
- MBCCOP - Hawaii
-
-
Idaho
-
Boise, Idaho, 미국, 83712
- Mountain States Tumor Institute - Boise
-
-
Illinois
-
Chicago, Illinois, 미국, 60612
- Veterans Affairs Medical Center - Chicago Westside Hospital
-
Hines, Illinois, 미국, 60141
- Veterans Affairs Medical Center - Hines
-
Maywood, Illinois, 미국, 60153-5500
- Cardinal Bernardin Cancer Center at Loyola University Medical Center
-
-
Indiana
-
Beech Grove, Indiana, 미국, 46107
- Indiana Blood and Marrow Transplantation
-
-
Kansas
-
Kansas City, Kansas, 미국, 66160-7353
- Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center
-
Wichita, Kansas, 미국, 67214-3882
- CCOP - Wichita
-
Wichita, Kansas, 미국, 67218
- Veterans Affairs Medical Center - Wichita
-
-
Kentucky
-
Lexington, Kentucky, 미국, 40502-2236
- Veterans Affairs Medical Center - Lexington
-
Lexington, Kentucky, 미국, 40536-0084
- Markey Cancer Center at University of Kentucky Chandler Medical Center
-
-
Louisiana
-
New Orleans, Louisiana, 미국, 70112
- Veterans Affairs Medical Center - New Orleans
-
New Orleans, Louisiana, 미국, 70112
- MBCCOP - LSU Health Sciences Center
-
New Orleans, Louisiana, 미국, 70115
- New Orleans Cancer Institute at Memorial Medical Center
-
New Orleans, Louisiana, 미국, 70112
- Tulane Cancer Center at Tulane University Hospital and Clinic
-
Shreveport, Louisiana, 미국, 71130-3932
- Feist-Weiller Cancer Center at Louisiana State University Health Sciences
-
Shreveport, Louisiana, 미국, 71101-4295
- Veterans Affairs Medical Center - Shreveport
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02114
- Massachusetts General Hospital Cancer Center
-
Boston, Massachusetts, 미국, 02118
- Cancer Research Center at Boston Medical Center
-
-
Michigan
-
Ann Arbor, Michigan, 미국, 48109-0948
- University of Michigan Comprehensive Cancer Center
-
Detroit, Michigan, 미국, 48201-1379
- Barbara Ann Karmanos Cancer Institute
-
Detroit, Michigan, 미국, 48201-1932
- Veterans Affairs Medical Center - Detroit
-
Detroit, Michigan, 미국, 48202
- Josephine Ford Cancer Center at Henry Ford Health System
-
Southfield, Michigan, 미국, 48075
- Providence Cancer Institute at Providence Hospital - Southfield Campus
-
-
Mississippi
-
Jackson, Mississippi, 미국, 39216-4505
- University of Mississippi Medical Center
-
Jackson, Mississippi, 미국, 39216
- Veterans Affairs Medical Center - Jackson
-
-
Missouri
-
Kansas City, Missouri, 미국, 64131
- CCOP - Kansas City
-
Saint Louis, Missouri, 미국, 63110
- Saint Louis University Cancer Center
-
-
Montana
-
Billings, Montana, 미국, 59101
- CCOP - Montana Cancer Consortium
-
-
New Mexico
-
Albuquerque, New Mexico, 미국, 87108-5138
- Veterans Affairs Medical Center - Albuquerque
-
-
New York
-
Albany, New York, 미국, 12208
- Veterans Affairs Medical Center - Albany
-
New York, New York, 미국, 10016
- NYU Cancer Institute at New York University Medical Center
-
New York, New York, 미국, 10032
- Herbert Irving Comprehensive Cancer Center at Columbia University
-
Rochester, New York, 미국, 14642
- James P. Wilmot Cancer Center at University of Rochester Medical Center
-
-
Ohio
-
Cincinnati, Ohio, 미국, 45220-2288
- Veterans Affairs Medical Center - Cincinnati
-
Cleveland, Ohio, 미국, 44195-9001
- Cleveland Clinic Taussig Cancer Center
-
Dayton, Ohio, 미국, 45429
- CCOP - Dayton
-
Dayton, Ohio, 미국, 45428-1002
- Veterans Affairs Medical Center - Dayton
-
-
Oklahoma
-
Oklahoma City, Oklahoma, 미국, 73104
- Veterans Affairs Medical Center - Oklahoma City
-
Oklahoma City, Oklahoma, 미국, 73104
- Oklahoma University Medical center
-
-
Oregon
-
Portland, Oregon, 미국, 97225
- CCOP - Columbia River Oncology Program
-
Portland, Oregon, 미국, 97201-3098
- Cancer Institute at Oregon Health and Science University
-
-
South Carolina
-
Charleston, South Carolina, 미국, 29401-5799
- Veterans Affairs Medical Center - Charleston
-
Greenville, South Carolina, 미국, 29615
- CCOP - Greenville
-
-
Tennessee
-
Memphis, Tennessee, 미국, 38104
- University of Tennessee Cancer Institute at Methodist Central Hospital
-
-
Texas
-
Amarillo, Texas, 미국, 79106
- Veterans Affairs Medical Center - Amarillo
-
Houston, Texas, 미국, 77030
- Baylor College of Medicine
-
Lackland Air Force Base, Texas, 미국, 78236-5300
- Wilford Hall Medical Center
-
Lubbock, Texas, 미국, 79415-3364
- UMC Southwest Cancer and Research Center
-
San Antonio, Texas, 미국, 78229-3900
- University of Texas Health Science Center at San Antonio
-
San Antonio, Texas, 미국, 78229
- Veterans Affairs Medical Center - San Antonio (Murphy)
-
Temple, Texas, 미국, 76504
- Veterans Affairs Medical Center - Temple
-
-
Utah
-
Salt Lake City, Utah, 미국, 84148
- Veterans Affairs Medical Center - Salt Lake City
-
Salt Lake City, Utah, 미국, 84132
- Huntsman Cancer Institute at University of Utah
-
-
Washington
-
Seattle, Washington, 미국, 98101
- CCOP - Virginia Mason Research Center
-
Seattle, Washington, 미국, 98108
- Veterans Affairs Medical Center - Seattle
-
Seattle, Washington, 미국, 98109-1024
- Fred Hutchinson Cancer Research Center
-
Seattle, Washington, 미국, 98104
- Swedish Cancer Institute at Swedish Medical Center - First Hill Campus
-
Tacoma, Washington, 미국, 98431-5000
- Madigan Army Medical Center
-
Tacoma, Washington, 미국, 98405-0986
- CCOP - Northwest
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
DISEASE CHARACTERISTICS:
- Morphologically confirmed acute myeloid leukemia (AML) (within 180 days of diagnosis) OR
- Secondary AML (secondary to myelodysplastic syndromes (MDS) or to prior leukemogenic therapy)
- Must have A1 marrow, B1 blood, and C1 extramedullary disease status
- Must have received prior remission induction chemotherapy
- Must have a genotypically HLA-identical sibling donor available that is not a monozygotic identical twin
- No M3 AML or blastic transformation of chronic myelogenous leukemia
- If history of CNS leukemia, no leukemia cells in CNS by lumbar puncture within past 7 days
- Must be concurrently enrolled on protocols SWOG-9007 and SWOG-S9910
PATIENT CHARACTERISTICS:
Age
- 55 to 69
Performance status
- Zubrod 0-2
Life expectancy
- Not specified
Hematopoietic
- See Disease Characteristics
Hepatic
- Not specified
Renal
- Not specified
Other
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- HIV negative
No other malignancy within the past 2 years except for the following:
- Adequately treated basal cell or squamous cell skin cancer
- Carcinoma in situ of the cervix
- Adequately treated stage I or II cancer in complete remission
PRIOR CONCURRENT THERAPY:
Biologic therapy
- No prior allogeneic hematopoietic stem cell transplantation
Chemotherapy
- See Disease Characteristics
- Prior consolidation therapy allowed
Endocrine therapy
- Not specified
Radiotherapy
- Not specified
Surgery
- Prior organ transplantation allowed provided not concurrently receiving immunosuppressive therapy
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: treatment
patient conditioning - fludarabine 30 mg/m2 IV over 1 hour Days -4, -3, -2; TBI 6-7 cGy/min Day 0 post-transplant immunosuppression - cyclosporine 6.25 mg/kg bid PO D -3 to +180 (begin taper on D+35); mycophenolate mofetil 15mg/kg bid PO D0 to +27
|
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Overall Survival
기간: 1 year
|
measured from date of registration to study until death from any cause with patients still alive censored at date of last contact
|
1 year
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Serious Adverse Events
기간: 9 months
|
Twice a week for the first two months, one time a week during month 3, one time every two weeks for months 4-9.
|
9 months
|
공동 작업자 및 조사자
수사관
- 연구 의자: Peter McSweeney, MD, Rocky Mountain Cancer Centers - Denver Midtown
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- S0125 (기타 식별자: SWOG)
- U10CA032102 (미국 NIH 보조금/계약)
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
방사선 요법에 대한 임상 시험
-
Alpha Tau Medical LTD.European Organisation for Research and Treatment of Cancer - EORTC아직 모집하지 않음
-
Alpha Tau Medical LTD.모병
-
Alpha Tau Medical LTD.모병
-
Alpha Tau Medical LTD.모집하지 않고 적극적으로